{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T22:45:40Z","timestamp":1792363540509,"version":"4.4.0"},"reference-count":55,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: Muscle symptoms are the most visible adverse event attributed to statins, but terminology is often imprecise. Most patients report myalgia or nonspecific aches, whereas objective myopathy, inflammatory or necrotizing myositis, rhabdomyolysis, and anti-HMGCR immune-mediated necrotizing myopathy are uncommon and clinically distinct entities. To provide a clinically oriented narrative synthesis of statin-associated muscle symptoms (SAMS) and severe statin-associated myotoxicity, and to propose a practical prevention, evaluation, and management algorithm. The classification of muscle events is used to standardize terminology and avoid diagnostic confusion, not to create a new formal taxonomy. Materials and Methods: A clinically oriented narrative review was performed using PubMed, Google Scholar, and major society documents published from January 2021 to April 2026. Eligible sources addressed SAMS, statin myopathy\/myositis, rhabdomyolysis, anti-HMGCR immune-mediated necrotizing myopathy, nocebo\/drucebo effects, pharmacogenetics, drug interactions, diagnosis, or management. The final evidence set comprised 55 verifiable sources, including blinded randomized or n-of-1\/crossover evidence; meta-analyses; clinical statements and reviews; pharmacovigilance analyses; pharmacogenetic guidance; mechanism-focused reviews; anti-HMGCR series; and lipid-lowering guideline\/treatment studies. Because the review was narrative, no pooled estimate or formal PRISMA screening log was generated. Results: Blinded evidence indicates only a small absolute excess of muscle pain with statins, concentrated mainly in the first year of therapy, and that most muscle symptoms reported during statin therapy are not pharmacologically caused by the statin. N-of-1 and crossover trials show that symptom intensity is often similar during statin and placebo periods, consistent with an important nocebo\/drucebo contribution. Severe muscle toxicity can nevertheless occur, especially when systemic statin exposure is increased by a high dose, interacting drugs, frailty, renal or hepatic impairment, hypothyroidism, transporter or metabolic genotypes, or intense unaccustomed exercise. Statin choice matters chiefly through dose, pharmacokinetics, and interaction burden. Conclusions: SAMS are common as reported clinical problems, but confirmed statin-caused muscle injury is substantially less frequent than routine clinical attribution suggests. Permanent discontinuation should be reserved for carefully assessed cases. A structured approach\u2014baseline risk assessment, selective CK measurement, exclusion of alternative causes, correction of modifiable risks, dechallenge\/rechallenge, statin switching, dose reduction, and combination with non-statin therapy\u2014preserves cardiovascular benefit while protecting the rare patient with genuine toxicity.<\/jats:p>","DOI":"10.3390\/medicina62061134","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:48:35Z","timestamp":1781138915000},"page":"1134","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Statin-Associated Muscle Symptoms and Myotoxicity: A Clinically Oriented Narrative Review with a Practical Prevention, Evaluation, and Management Algorithm"],"prefix":"10.3390","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5547-4025","authenticated-orcid":false,"given":"Francisco","family":"Epelde","sequence":"first","affiliation":[{"name":"Internal Medicine Department, Parc Taul\u00ed Hospital Universitari, Institut d\u2019Investigaci\u00f3 i Innovaci\u00f3 Parc Taul\u00ed (I3PT-CERCA), Universitat Aut\u00f2noma de Barcelona, 08202 Sabadell, Barcelona, Spain"},{"name":"Internal Medicine, Aptima Centre Clinic, 08221 Terrassa, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"3213","DOI":"10.1093\/eurheartj\/ehac015","article-title":"Prevalence of statin intolerance: A meta-analysis","volume":"43","author":"Penson","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.jacl.2022.05.068","article-title":"NLA scientific statement on statin intolerance: A new definition and key considerations for ASCVD reduction in the statin-intolerant patient","volume":"16","author":"Cheeley","year":"2022","journal-title":"J. Clin. Lipidol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jacl.2022.09.001","article-title":"Assessment and management of statin-associated muscle symptoms (SAMS): A clinical perspective from the National Lipid Association","volume":"17","author":"Warden","year":"2023","journal-title":"J. Clin. Lipidol."},{"key":"ref_4","unstructured":"Cholesterol Treatment Trialists\u2019 Collaboration (2022). Effect of statin therapy on muscle symptoms: An individual participant data meta-analysis of large-scale, randomised, double-blind trials. Lancet, 400, 832\u2013845."},{"key":"ref_5","unstructured":"Cholesterol Treatment Trialists\u2019 (CTT) Collaboration (2026). Assessment of adverse effects attributed to statin therapy in product labels: A meta-analysis of double-blind randomised controlled trials. Lancet, 407, 689\u2013703."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"n135","DOI":"10.1136\/bmj.n135","article-title":"Statin treatment and muscle symptoms: Series of randomised, placebo controlled n-of-1 trials","volume":"372","author":"Herrett","year":"2021","journal-title":"BMJ"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1016\/j.jacc.2021.07.022","article-title":"Side effect patterns in a crossover trial of statin, placebo, and no treatment","volume":"78","author":"Howard","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1002\/jcsm.12960","article-title":"Step-by-step diagnosis and management of the nocebo\/drucebo effect in statin-associated muscle symptoms patients: A position paper from the International Lipid Expert Panel (ILEP)","volume":"13","author":"Penson","year":"2022","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"4787","DOI":"10.1093\/eurheartj\/ehab358","article-title":"Nocebo\/drucebo effect in statin-intolerant patients: An attempt at recommendations","volume":"42","author":"Penson","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s11883-024-01246-y","article-title":"Statin-associated muscle symptoms: Identification and recommendations for management","volume":"27","author":"Maki","year":"2024","journal-title":"Curr. Atheroscler. Rep."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1007\/s11926-024-01143-y","article-title":"Decoding the intricacies of statin-associated muscle symptoms","volume":"26","author":"Rastegar","year":"2024","journal-title":"Curr. Rheumatol. Rep."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.pcad.2022.11.010","article-title":"Statin associated muscle symptoms: An update and review","volume":"75","author":"Dicken","year":"2022","journal-title":"Prog. Cardiovasc. Dis."},{"key":"ref_13","first-page":"602","article-title":"Statin-associated muscle symptoms: Myth or reality?","volume":"222","year":"2022","journal-title":"Rev. Clin. Esp."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e15337","DOI":"10.1111\/1756-185X.15337","article-title":"Statin-associated muscle symptoms: A comprehensive exploration of epidemiology, pathophysiology, diagnosis, and clinical management strategies","volume":"27","author":"Shah","year":"2024","journal-title":"Int. J. Rheum. Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1080\/17512433.2025.2565619","article-title":"Statin associated muscle symptoms in older adults","volume":"18","author":"Pogge","year":"2025","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.eprac.2023.03.004","article-title":"Statin intolerance: A review and update","volume":"29","author":"Tsushima","year":"2023","journal-title":"Endocr. Pract."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"101714","DOI":"10.1016\/j.beem.2022.101714","article-title":"Management of patients with statin intolerance","volume":"37","author":"Martirossian","year":"2023","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s11883-023-01124-z","article-title":"Statin intolerance: An overview of US and international guidance","volume":"25","author":"Cheeley","year":"2023","journal-title":"Curr. Atheroscler. Rep."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1080\/14779072.2023.2215982","article-title":"Statin associated muscle symptoms (SAMS): Strategies for prevention, assessment and management","volume":"21","author":"Iatan","year":"2023","journal-title":"Expert Rev. Cardiovasc. Ther."},{"key":"ref_20","unstructured":"Feingold, K.R., Anawalt, B., Blackman, M.R., Chrousos, G., Corpas, E., de Herder, W.W., Dhatariya, K., Dungan, K., Hamilton, E., and Hofland, J. (2025). Cholesterol lowering drugs. Endotext [Internet], MDText.com."},{"key":"ref_21","unstructured":"Sizar, O., Khare, S., Jamil, R.T., and Talati, R. (2025). Statin Medications. StatPearls [Internet], StatPearls Publishing."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1111\/bcp.15757","article-title":"Rhabdomyolysis and statins: A pharmacovigilance comparative study between statins","volume":"89","author":"Montastruc","year":"2023","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Morris, R., Bu, K., Han, W., Wood, S., Hernandez Velez, P.M., Ward, J., Crescitelli, A., Martin, M., and Cheng, F. (2025). The association between statin drugs and rhabdomyolysis: An analysis of FDA Adverse Event Reporting System (FAERS) data and transcriptomic profiles. Genes, 16.","DOI":"10.3390\/genes16030248"},{"key":"ref_24","first-page":"e81260","article-title":"Comparative analysis of adverse event profiles among seven statins for hypercholesterolemia management using the United States FDA Adverse Event Reporting System","volume":"17","author":"Ogura","year":"2025","journal-title":"Cureus"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1007\/s10557-023-07459-8","article-title":"Rhabdomyolysis with co-administration of statins and antiplatelet therapies-analysis of the WHO pharmacovigilance database","volume":"38","author":"Roule","year":"2024","journal-title":"Cardiovasc. Drugs Ther."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Zhang, S., Yan, M.M., Zhao, H., Qiu, X.Y., and Zhu, D. (2024). Rhabdomyolysis associated with concomitant use of colchicine and statins in the real world: Identifying the likelihood of drug-drug interactions through the FDA Adverse Event Reporting System. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1445324"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s00228-025-03968-7","article-title":"Prevalence of substances with OATP1B1 inhibitory properties in individual case safety reports of suspected statin-associated myopathy: An analysis of Swiss pharmacovigilance data","volume":"82","author":"Stauble","year":"2026","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"211","DOI":"10.2147\/DHPS.S333738","article-title":"A narrative review of statin-induced rhabdomyolysis: Molecular mechanism, risk factors, and management","volume":"13","author":"Safitri","year":"2021","journal-title":"Drug Healthc. Patient Saf."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Yoon, J., Kim, S.W., Kim, S.H., Song, J.J., Park, Y.-B., Park, H.J., Shin, H.Y., Park, S.H., and Rhee, Y. (2025). Clinical characteristics and management of statin-associated anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase immune-mediated necrotizing myopathy. J. Clin. Med., 14.","DOI":"10.3390\/jcm14186610"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"4995","DOI":"10.1093\/rheumatology\/keaf238","article-title":"The incidence of anti-HMGCR immune-mediated necrotizing myopathy: An Australian and UK retrospective multi-site cohort study","volume":"64","author":"Khoo","year":"2025","journal-title":"Rheumatology"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s40801-025-00481-2","article-title":"Trends in reports of statin-associated immune-mediated necrotizing myopathy using the Japanese Adverse Drug Event Report database","volume":"12","author":"Takami","year":"2025","journal-title":"Drugs Real World Outcomes"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"34884","DOI":"10.1038\/s41598-025-17766-9","article-title":"Clinical-pathologic classification of anti-HMGCR-positive immune-mediated necrotizing myopathy","volume":"15","author":"Cao","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.jacl.2025.12.026","article-title":"Use of mobile health technology in the assessment of statin-associated muscle symptoms: A pilot feasibility study","volume":"20","author":"Sathiyakumar","year":"2026","journal-title":"J. Clin. Lipidol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"100981","DOI":"10.1016\/j.lanepe.2024.100981","article-title":"Quality of life in patients with statin intolerance: A multicentre prospective registry study","volume":"43","author":"Mateev","year":"2024","journal-title":"Lancet Reg. Health Eur."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1001\/jamacardio.2022.4250","article-title":"Statin-associated muscle symptoms among new statin users randomly assigned to vitamin D or placebo","volume":"8","author":"Hlatky","year":"2023","journal-title":"JAMA Cardiol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/j.jacc.2023.01.043","article-title":"Prolonged moderate-intensity exercise does not increase muscle injury markers in symptomatic or asymptomatic statin users","volume":"81","author":"Allard","year":"2023","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1007\/s11606-021-06651-6","article-title":"The risk of muscular events among new users of hydrophilic and lipophilic statins: An observational cohort study","volume":"36","author":"Mueller","year":"2021","journal-title":"J. Gen. Intern. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1002\/cpt.2557","article-title":"The Clinical Pharmacogenetics Implementation Consortium guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and statin-associated musculoskeletal symptoms","volume":"111","author":"Niemi","year":"2022","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"399","DOI":"10.2217\/pgs-2023-0056","article-title":"SLCO1B1 gene-based clinical decision support reduces statin-associated muscle symptoms risk with simvastatin","volume":"24","author":"Massmann","year":"2023","journal-title":"Pharmacogenomics"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/s41431-024-01769-7","article-title":"Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between SLCO1B1 and statins and CYP2C9 and sulfonylureas","volume":"33","author":"Wolthuis","year":"2025","journal-title":"Eur. J. Hum. Genet."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"118624","DOI":"10.1016\/j.atherosclerosis.2024.118624","article-title":"Publication bias in pharmacogenetics of statin-associated muscle symptoms: A meta-epidemiological study","volume":"400","author":"Gougeon","year":"2025","journal-title":"Atherosclerosis"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"3799","DOI":"10.1111\/bph.17309","article-title":"Off-target effects of statins: Molecular mechanisms, side effects and the emerging role of kinases","volume":"181","author":"Liepinsh","year":"2024","journal-title":"Br. J. Pharmacol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.jare.2024.12.020","article-title":"Advances in statin adverse reactions and the potential mechanisms: A systematic review","volume":"76","author":"Zeng","year":"2025","journal-title":"J. Adv. Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"107912","DOI":"10.1016\/j.phrs.2025.107912","article-title":"Statin drugs and lipid modulation: Mechanistic basis considering lipid rafts, kinase signaling, myopathy, and cancer","volume":"220","author":"Karthikeyan","year":"2025","journal-title":"Pharmacol. Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1161\/CIR.0000000000001168","article-title":"2023 AHA\/ACC\/ACCP\/ASPC\/NLA\/PCNA guideline for the management of patients with chronic coronary disease: A report of the American heart association\/American college of cardiology joint committee on clinical practice guidelines","volume":"148","author":"Virani","year":"2023","journal-title":"Circulation"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/j.jacc.2022.07.006","article-title":"2022 ACC expert consensus decision pathway on the role of nonstatin therapies for LDL-cholesterol lowering in the management of ASCVD risk","volume":"80","author":"Morris","year":"2022","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"3415","DOI":"10.1093\/eurheartj\/ehae177","article-title":"2024 ESC guidelines for the management of chronic coronary syndromes","volume":"45","author":"Vrints","year":"2024","journal-title":"Eur. Heart J."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/S0140-6736(22)00916-3","article-title":"Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): A randomised, open-label, non-inferiority trial","volume":"400","author":"Kim","year":"2022","journal-title":"Lancet"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1001\/jama.2023.2487","article-title":"Treat-to-target or high-intensity statin in patients with coronary artery disease: A randomized clinical trial","volume":"329","author":"Hong","year":"2023","journal-title":"JAMA"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e075837","DOI":"10.1136\/bmj-2023-075837","article-title":"Rosuvastatin versus atorvastatin treatment in adults with coronary artery disease: Secondary analysis of the randomised LODESTAR trial","volume":"383","author":"Lee","year":"2023","journal-title":"BMJ"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1056\/NEJMoa2215024","article-title":"Bempedoic acid and cardiovascular outcomes in statin-intolerant patients","volume":"388","author":"Nissen","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1001\/jama.2023.9696","article-title":"Bempedoic acid for primary prevention of cardiovascular events in statin-intolerant patients","volume":"330","author":"Nissen","year":"2023","journal-title":"JAMA"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"e2113186","DOI":"10.1001\/jamanetworkopen.2021.13186","article-title":"Cardiovascular outcomes and mortality associated with discontinuing statins in older patients receiving polypharmacy","volume":"4","author":"Rea","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"e2136802","DOI":"10.1001\/jamanetworkopen.2021.36802","article-title":"Statin discontinuation and cardiovascular events among older people in Denmark","volume":"4","author":"Thompson","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Aygun, S., and Tokgozoglu, L. (2022). Comparison of current international guidelines for the management of dyslipidemia. J. Clin. Med., 11.","DOI":"10.3390\/jcm11237249"}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/6\/1134\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T01:25:18Z","timestamp":1781141118000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/6\/1134"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,10]]},"references-count":55,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["medicina62061134"],"URL":"https:\/\/doi.org\/10.3390\/medicina62061134","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,10]]}}}